The FDA has granted Fast Track Designation to Adicet Bio’s ADI-001, an allogeneic gamma delta CAR T-cell therapy, for ...

Adicet Bio, Inc. (ACET), a clinical stage biotechnology company, Wednesday said it received Fast Track Designation from the U.S. Food ...

Adicet Bio, Inc. (Market cap: $75.8M), a biopharmaceutical company currently rated 'FAIR' by InvestingPro's Financial Health scoring system, has announced updates on the enrollment of its clinical ...

Adicet Bio (ACET) announced the FDA has granted fast track designation to ADI-001 for the potential treatment of adult patients with refractory ...

Thinking about participating in a clinical trial? Here are 15 questions to ask your doctor about clinical trials for you make ...

In this article, we explore the experiences of sickle cell patients in emergency care and the ways they can advocate for themselves ...

Financial writer recommends Crispr Therapeutics AG as a strong buy due to cash position, drug pipeline, and promising ...

Using glucocorticoids, rituzimab, or certain immunosuppressants to treat connective tissue diseases is associated with greater risks for severe COVID-19-related outcomes.

Children with rheumatic diseases may face increased risks for COVID-19-related hospitalization, particularly those using glucocorticoids, rituximab, or mycophenolate.

Carisma Therapeutics Inc. ("Carisma" or the "Company"), a leader in macrophage-focused therapeutics, today announced that Steven Kelly, President and Chief Executive Officer, will participate in the ...